違憲? 警政署犯罪基因DNA資料庫??!

DNA資料庫／私密資料 如何確保不外洩 【2011/08/17 聯合報】警政署不思科學辦案、積極查案，反而以「罪犯有犯罪之基因」之思維，積極建立ＤＮＡ資料庫，好像只要犯過罪，就可能犯妨礙性自主罪，所以先從罪犯過濾。人權議題和資料庫管理問題必須有共識。這些高度私密的個人資料如何確保不外洩？假如外洩，人民的權益如何補救？一定會是政府頭痛的問題。以個人資料保護法為例，即使已經立法，卻還是不時發生個人資料外洩的案例，要追查洩漏者也不是那麼容易。警政署的出發點應該很單純的要積極的破案。但是ＤＮＡ資料庫的採樣和管理茲事體大，嚴重侵犯個人的隱私，政策的決定朝野應更為審慎。當初戶籍法修正案強制民眾按捺指紋才能換發身分證，並建立指紋資料庫，同樣引發反彈，後來更被大法官會議宣告違憲。大法官林子儀更在協同意見書中表示，「假使今天同意政府可以為了偵查犯罪，要求全國人民交出指紋資訊予以建檔，則當政府以同樣的理由，要求人民交出ＤＮＡ遺傳資訊、記錄虹膜等，又豈能拒絕。」更是真知灼見。如果國家所有人民資訊都鉅細靡遺地掌握在國家機器之中，或許能營造一個零犯罪的社會，但人們也將活在完全被監視、充滿恐懼的「楚門的世界」，恐怕沒有人願意如此犧牲。

台灣生技創投基金暫不投上市櫃醫材公司

台灣生技創投基金啟動投資 自由時報 台灣生技創投基金（TMF）經營團隊昨天正式亮相，未來手握50億元資金的基金管理團隊負責人張有德昨天表示，目前已選定多個案子進行評估，包括心血管手術、胃腔鏡等置入式、微創式的高階醫療器材為主，他認為台灣醫材業正面對中國快速成長，這是一個千載難逢的機會；昨天醫材股除了受此激勵外，今天將登場的櫃買中心生技法說會，相關股股價也相對亮麗。目前已上市櫃的醫材股包括：曜亞（4138）、華廣（4737）、太醫（4126）、五鼎（1733）、百略（4103）、聯合骨科（4129）等，其中不乏獲利高、股價高逾百元的個股，不過張有德表示，TMF暫時不會投資已經上市櫃的公司，除非相關公司有私募資金規劃，來進行更好的投資案，TMF才有興趣。張有德分析，目前美國仍是醫療保健支出最大的國家，佔其GDP將近16%，且不受景氣影響，穩定成長。張有德指出，去年全球醫材市場約為2,456億元，其中美洲佔了44%，西歐為28%，亞太地區為19%，而以亞太地區成長最快，未來全球市場將以每年4%-6%幅度成長，估計2013年可達2,841億元，其中中國成長幅度將相對驚人。張有德表示，TMF投資標的將以高獲利的醫材產業為主，旗下會成立一家生醫科技旗艦公司及育成中心，旗艦公司負責收購及專利授權，育成中心負責公司養成。

台灣生技創投基金 (TMF)將成立育成公司

生技創投基金啟動 官民共孵小金雞 規模50億元 年底資金可到位 傳鴻海有意入股2011年 08月17日 【姚惠珍、王郁倫╱台北報導】肩負推動台灣生技醫療產業為未來明星產業的台灣生技創投基金（TMF）昨邀智融集團擔任顧問，正式啟動對外募資計劃。TMF董事長張有德表示，基金規模50億元中，除國發基金投資2成外，中油、中鋼（2002）等國營事業也將投資2成，其餘6成將向民間募資，張有德說：「預計年底資金將可到位，明年即可正式運作。」對於外傳鴻海（2317）集團有意入股，張有德未否認，僅表示接觸對象很多，不管是科技、傳產或金融，都有企業表達投資意願。張有德說：「過段時間，有投資意願的企業就會明朗化。」

6成資金向民間募集  至於是否拜訪有家族疾病經驗的企業主洽談投資機會，張有德僅說，目前無可奉告。張有德指出，由於TMF有扶植醫療器材產業的使命，因此未來將會成立育成公司，主動發掘學術單位的創新研究，扶植初創期的企業，張有德說：「若是已具規模的上市櫃企業，除非有研發需求要募資，否則TMF較不會投資。」至於具體投資標的，張有德不願透露，僅表示主要可分為2大類，一是治療疾病過程所需的醫療器材，像是心血管支架、骨科（人工關節）等；其次則是居家照護設備，如偵測睡眠狀態的儀器等。智融集團董事長施振榮則表示，台灣對世界的價值在於貢獻在哪，像是上一波的資通訊產業，台灣就有很大的貢獻，但是全世界都知道蘋果電腦或是手機，就很少人知道台灣對蘋果電腦的貢獻。施振榮說：「關鍵在於沒有華人的品牌，現在兩岸簽訂ECFA(Economic Cooperation Framework Agreement，兩岸經濟合作架構協議)後，台灣生技業有很大的機會，因有中國廣大的市場，台灣的創新才有發展商機，有了商機，建立國際性的華人品牌不是不可能。」施振榮強調，只要站穩中國市場，歐美不可能不買單，所以台灣生技業是台灣這一波產業的發展重點。

國發基金將投資2成 而下午研討會中，經濟部次長黃重球也以兩岸簽訂ECFA後，人工關節出口到中國享有零關稅政策為例說：「上半年台灣出口到中國的人工關節金額年增率逾42%，顯示中國龐大的商機。」國發基金確定投資TMF 2成，金額約10億元，其餘2成則由國營事業如中鋼、中油、台糖、台鹽等出資，其餘6成則由民間募資。

經建會副主委胡仲英表示，國發基金至今投資生技業約107億元，其中直接投資國光生技、神隆及太景等12家，金額約45億元，都將陸續進入收成期。

台灣生技創投基金 (TMF)小檔案 ◎董事長：張有德◎基金規模：50億元◎資金來源：●國發基金20%●中鋼、台糖等國營事業20%●民間資金60%◎投資標的：●醫療器材或新藥研發●亞洲人特有的心血管疾病、骨科相關的醫材或新藥◎目前籌設進度：尋找適當投資標的，資金年底到位後即可投資

景岳彌補塑化劑風暴影響 出脫第一生化持股!!

景岳賣第一生化進補2011-08-16 【時報】景岳（3164）受塑化劑風暴襲擊，上半年恐現近年首見虧損，宣布處分部分第一生化持股美化財報，交易金額1.03億元，總計處分利益7,464萬元，貢獻每股獲利達1.38元。景岳自結7月營收996萬元，首度跌破千萬元大關，創近年新低，月減率32.43％，年減率高達55.08％；累計前7月營收1.1億元，年減41.91％。法人表示，景岳首季稅後盈餘583萬元，年減率達87.02％，EPS僅0.11元；第2季在塑化劑風暴持續打壓下，業績再下修，加上還有回收產品和賠償問題，單季出現虧損，預估上半年每股稅後淨損將逾1元，不過景岳祭出處分轉投資公司第一生化的股票，對年度獲利應有挹注。

金管會證期局核備 康聯控股上市案

康聯控股上市獲核備 中央商情網 2011-08-16  行政院金融監督管理委員會證券期貨局核備康聯控股公司申請上市案。康聯控股 (Coland Holdings Limited)為專業醫藥開發與行銷服務公司，康聯也是首家申請第一上市的外國生技醫療企業。康聯註冊於英屬開曼群島，股本新台幣6.22億元，，主要產品包括肝炎、神經系統、抗腫瘤、呼吸系統、脊柱內固定產品，以及抗生素等。

健喬買回庫藏股進度!!

健喬買回庫藏股160.4萬股，平均每股30.23元 2011-08-16 【時報-台北電】健喬信元(4114)公告第五次買回庫藏股期間屆滿未執行完畢。健喬本次買回庫藏股160萬4000股，總金額4848萬4081元，平均每股30.23元，累積已持有自家股票425萬9000股，占已發行股份總數5.19%。健喬表示，為維護整體股東權益，公司視股價變化採分批買回策略，故未能執行完畢。

 

Reference: 健喬信元花費一億元投資看好未來潛力

GSK, partner Impax plan 4Q NDA for new Parkinson’s drug

8.15.2011 An investigational Parkinson's disease treatment licensed by GlaxoSmithKline (NYSE:GSK) is now slated for a fourth-quarter new drug application with U.S. regulators following positive late-stage clinical trial results. British pharmaceutical giant GSK, which has its U.S. headquarters in Research Triangle Park, North Carolina, is partnering with California-based Impax Pharmaceuticals, a division of Impax Laboratories (NASDAQ:IPXL), to develop the compound IPX066 in phase 3 clinical trials. IPX066 is an extended release formulation of the combination drug carbidopa-levodopa. GSK said trial results show that the compound, being studied as a treatment for motor symptoms of Parkinson's disease, worked better than an existing treatment, carbidopa-levodopa plus the drug entacapone. Novartis (NYSE:NVS) markets that patented drug combination under the name Stalevo. Stalevo and entacopone, which is marketed as Comtan, together generated $600 million in 2010 sales, according to Novartis. AdvertisementThe IPX066 phase 3 study measured "off time," the time when the medication has worn off and Parkinson's symptoms return. IPX066 results showed a 33.5 percent decrease in off time. Stalevo only showed a 10 percent decrease in off time. For Parkinson's patients, IPX066′s results translates into an 84 minute improvement. GSK said that full results from the trial will be presented at an upcoming scientific meeting. A new Parkinson's drug would be a win for GSK, which licensed rights to the Impax compound last December. The deal gave Impax an $11.5 million up-front payment and potential payments up to $175 million if the drug candidate hits development and commercialization milestones. Impax will also receive double-digit royalties on GSK's sales of the drug. Impax will file the U.S. new drug application. GSK has the worldwide commercialization rights for IPX066, except for the United States and Taiwan. GSK plans to file a marketing application for IPX066 in Europe in 2012.

年輕族群 勿輕忽大腸癌警訊!

年輕大腸癌患者 預後存活差（中央社）2011-08-16大腸直腸癌排名民眾癌症發生率的首位；奇美醫學中心研究發現，年齡小於40歲、沒有家族病史者一旦罹患大腸直腸癌，通常會有較惡性的腫瘤形態，預後及存活也較不好。研究大腸直腸癌的奇美醫學中心一般外科醫師周家麟今天指出，健保資料庫資料顯示，民國87年至94年間，大腸直腸癌罹病年齡有逐漸老年化的趨勢，小於40歲診斷出大腸直腸癌的病人，在這8年間呈現平穩趨勢，代表台灣罹患大腸直腸癌者沒有年輕化的趨勢。不過，周家麟研究發現，小於40歲、沒有大腸直腸癌家族史的年輕病人，卻有較惡性的腫瘤形態、較差的癌症期別及較不良好的預後存活。周家麟表示，罹癌年輕病人最常見求診症狀是解血便及腹痛，8成的年輕罹癌者手術後需做化學藥物治療，高達4成的年輕病人，診斷出罹患大腸直腸癌時，就已是第4期，有腫瘤遠處轉移。周家麟說，這些年輕罹癌病人即使接受積極的手術和化學藥物治療，有些人的5年存活率，甚至比年紀大於80歲的大腸直腸癌老年病人來的差。周家麟認為，年輕罹癌者預後較差，主要是較差的癌症期別，因年輕人體力好，對身體不適也較能忍耐，容易忽略解血便及腹痛的警訊，加上沒有家族病史，使得患者及臨床醫師誤認罹癌機率低，造成延遲診斷，才讓年輕患者有較晚的癌症期別。周家麟的這項研究時間長達10年，以台北榮民總醫院2001年至2006年的大腸直腸癌患者作為研究對象，被研究患者共有322人，其中69人是小於40歲、沒有家族病史的患者，其餘都是大於80歲的患者。周家麟的這篇研究，已投稿到美國外科醫學論文雜誌（The American Journal of Surgery），且已被接受，將於9月發表。

Cel-Sci expands Teva's Multikine cancer license

Teva will have exclusivity in Serbia and Croatia, in addition to Turkey and Israel. 20 July 11 Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) and Cel-Sci Corporation (AMEX: CVM) have expanded their licensing agreement for Cel Sci's head and neck cancer treatment Miltikine,. Cel-Sci expanded Teva's exclusive marketing license for the drug from Israel and Turkey to Croatia and Serbia. Multikine is undergoing a global Phase III clinical trial, including at three hospitals in Israel, which Teva is funding. Teva will bear the registering and selling costs of the drug in Serbia and Croatia and will pay Cel-Sci milestone payments after the drug is approved. The two companies will share the revenue generated in all four countries. The Israeli trial will begin at Soroka Medical Center in Beersheva, where registration is due to begin shortly. The full global trial is due to include 880 patents at 40 hospitals in nine countries. Taiwan's Orient Europharma Co. Ltd. (Taipei: 4120) is also a party in the Multikine clinical trial, which aims to set a new standard of treatment for head and neck cancer. The Phase II clinical trial found that Multikine killed 12% of the cancer cells within a month, and the treatment regime can kill half the tumor cells before chemotherapy begins, boosting patients' survival rates by 33%. Cel-Sci CEO Geert Kersten said, "We are pleased to expand our relationship with Teva. Strengthening this relationship will help in maximizing Multikine's potential in developing markets while retaining rights to market Multikine in North America and most of Europe." Teva's share price rose 1.1% on Nasdaq yesterday to $47.80, giving a market cap of $44.9 billion, and rose 0.1% by mid-afternoon on the TASE today to NIS 164.20.

U.S. Stem Cell Companies Find Partners and Revenues Beyond the Water’s Edge

Aug 16, 2011  American companies focused on stem cell treatments and technology platforms have met with success in finding partnerships and revenues overseas in the past decade. And it's not for the reason many people might think, namely the controversy over U.S. federal funding of human embryonic stem cell (hESC) research. Two other factors better explain why U.S. stem cell companies have been looking beyond their borders to Asia, according to Bernard Siegel, founder and full-time executive director of the nonprofit Genetics Policy Institute (GPI). One is the attractiveness of Asian countries as markets for stem cell treatments. That reflects both high population concentrations as well as willingness by national governments to invest in stem cell research as well as companies commercializing such treatments and encourage additional research by outside parties. The other is Asia's lower regulatory hurdles when compared to the U.S."It's easier to move toward the translational process and get clinical trials cranked up in Asia than the United States," Siegel pointed out. "I think that's one aspect of it."U.S. companies can do that and more in Europe as well, if one company's experience is any indication. Cytori Therapeutics has won both initial and expanded indication approval in Europe for its Celution® System family of medical devices and instruments, which is not yet available in the U.S. Celution extracts and separates stem and regenerative cells from a patient's own adipose tissue."What we found as we moved through the European market is that that head-start was really important relative to the U.S. or other places," Cytori president Marc H. Hedrick, M.D., told GEN.

Japan's Position  The initial European approval allowed Cytori to expand into Japan where, Dr. Hedrick noted, the company obtained its first clinical experience. The company capitalized on the fact that doctors in Japan can, with a prescription, import technologies approved elsewhere."And it just so happened we had a relationship with one of the preeminent surgeons in Japan. In fact, our first 20 patients had breast cancer reconstructions performed in Japan at his university hospital," Dr. Hedrick recalled."At the same time, we identified someone to lead the charge in Japan, that we were very fortunate to get, who was a business leader at Baxter in Japan. One thing led to another, and we now have the majority of our revenues from Japan. And it was all tied back to that original regulatory approval in Europe that allowed us to get into that market very quickly," Dr. Hedrick added. Japan's share of Cytori's sales tumbled during the first quarter to 30% from 72% a year earlier due to the March 11 Tohoku earthquake and resulting tsunami. Japan is where Cytori, which maintains a Tokyo office, found two investors among some of the country's corporate giants. Last year Astellas agreed to buy $10 million of Cytori stock. And in 2008, Olympus, a medical device company, led a $17 million private placement financing. Two years prior Olympus made an $11 million milestone payment to Cytori for obtaining CE Mark approval for the original Celution system."They provided a significant amount of capital to Cytori, and that was another reason why it made sense to focus on the Japanese market," Dr. Hedrick said.

Other Countries in Asia Neuralstem is also involved in partnerships with Asian companies, with deals initially focused on research. While Neuralstem last year established a wholly owned subsidiary in China, it has yet to come to terms with commercial or regulatory collaborators.By year-end the firm plans to start a clinical trial in China focused on transplantation of cells into the brain to treat stroke. The trial would take place at Beijing's BaYi Brain Hospital, which has been working with Neuralstem to prepare a clinical protocol for treatment of motor deficits due to ischemic stroke. In Japan the company came to terms with the wholly owned subsidiary of Sumitomo, Summit Pharmaceuticals, to market development and licensing rights for NSI-189, Neuralstem's lead small molecule neurogenic compound. It is currently in an FDA-approved Phase I trial for major depression. The company has said it intends to take NSI-189 through Phase II trials before seeking a partner for worldwide rights. Neuralstem has also entered into collaborations in Taiwan, including one with China Medical University & Hospital, to advance development of its human spinal cord neural stem cell therapies for amyotrophic lateral sclerosis. It is also working with the hospital to commence a clinical trial focused on treating stroke. Additionally, in India, the company is planning a clinical trial for later this year to assess the ability of its cell therapy to treat spinal cord injury. The Indian market is so large that companies like Neuralstem need to find a technological partner first to ensure access to the best neurosurgeons it can find, according to Richard Garr, CEO. "We're happy to do the proof of principle human studies ourselves before we look for a commercial and regulatory partner." Neuralstem notes that it has done most of its proof of principle collaborations with American universities such as the University of California, San Diego and the University of Michigan. "We haven't gone overseas because we can't do it here in the U.S.," Garr remarked. "We went overseas because we believe those are their own independent markets." Garr points out that commercialization efforts for each country are independent of each other. "The other reason" to move into Asian countries, he added, "is because if you don't, someone else will. And then you end up in a fight trying to protect it." Neuralstem broke into Asia in 2008, when Korean conglomerate CJ CheilJedang (CJ) bought $2.5 million worth of Neuralstem stock. CJ has an exclusive option to Neuralstem's spinal cord cell products for five Asian nations: South Korea, Vietnam, Indonesia, Malaysia, and Singapore. CJ would have the responsibility to take the products through regulatory approvals and commercialization in their markets. Garr expects CJ to decide what its first clinical trial will be and where later this year. Another U.S. stem cell company that has teamed up with a Korean company is Advanced Cell Technology (ACT). In 2008, ACT joined with CHA Biotech to form a joint venture aimed at developing ACT's hESC-based hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases. On July 21, the companies announced that their venture, Stem Cell & Regenerative Medicine International (SCRMI), exclusively licensed the rights to the HG program to ACT for the U.S. and Canada and to CHA Biotech for Korea and Japan. "The partnership itself had research scientists working on trying to get things ready for starting human trials. And the way the deal works, ACT has hired substantially all the scientists that were working in the joint venture"—10 SCRMI employees in all, Gary Rabin, ACT's interim chairman and CEO, told GEN. Rabin said the first IND will be filed for using the HG platform to generate renewable sources of transfusable blood platelets. The platelets could unlock a significant opportunity for ACT, namely in the military wound-care market. Last year, Robert Lanza, M.D., ACT's CSO, and Kwang-Soo Kim, Ph.D., of Harvard University's McLean Hospital and the CHA Stem Cell Institute, won a $1.9 million NIH director's opportunity award to explore the potential of induced pluripotent stem cells (iPSCs) as a source of universal red blood cells and platelets for transfusion. Another Asian market ACT is keeping an eye on is China. In March the company reported that China's State Intellectual Property Office allowed its patent application to provide broad intellectual property protection for the manufacturing and pharmaceutical preparations of retinal pigment epithelial (RPE) cells from hESCs for degenerative retinal disease.ACT has initiated a Phase I study with the RPE therapy in the U.S. Additionally, ACT has launched human trials for Stargardt macular dystrophy and advanced dry age-related macular degeneration. Data from those trials is expected to be published this fall, after the first three patients are tested in both trials.

Working in Europe In Europe, Cytori won expanded approval for Celution last year. The sanction included new indications such as breast reconstruction, repair of soft tissue defects, as well as the facilitation of healing certain types of wounds such as those resulting from Crohn disease. "We're relatively close, we think, to getting approval for cardiac disease," Dr. Hedrick added. "And we're actually beginning to get reimbursement and working toward our own diagnosis-related group payments for the technology in Europe. So that series of decisions, predicated all on the early regulatory approval of the device, has really pushed us down the road of being very active in Europe." Cytori sees more potential partnerships among global medical device companies across Europe, particularly in Switzerland, where the company has an office in Zug. Neuralstem is collaborating with Albert-Ludwigs-University in Freiburg, Germany, on a treatment for Huntington disease. It also plans on undertaking a chronic spinal cord injury trial using spinal cord cells being developed at the Czech Institute of Experimental Medicine. The ability of the European market to grow as a stem cell mecca will hinge, Siegel said, on the outcome of a pending court case that—while different on specifics—parallels the U.S. debate over hESC funding. Later this year the Court of Justice of the European Union is expected to decide whether to side with its advocate general, who termed stem cell patents "contrary to ethics and public policy," or with Oliver Brüstle, Ph.D., who since 2004 has fought to maintain a 1997 patent covering methods for deriving neural cells from hESCs despite a challenge from Greenpeace. Dr. Brüstle is director of the Institute of Reconstructive Neurobiology at the University of Bonn. A decision against Dr. Brüstle would cement Asia's place on the hESC end of stem cell research and commercialization. The U.S. remains schizophrenic, with President Barack Obama's administration scrambling to approve new hESC lines, while the Sherley v. Sebelius court case and the nation's political divide keep federal funding from being a certainty. Yet all of that doesn't necessarily hurt U.S. stem cell companies. As the past few years have demonstrated, they are perfectly capable of following the money and partners in pursuit of the science and show no signs of pulling back from their overseas activity.

For Longer Life, Exercise 15 Minutes A Day And Cut TV Hours

16 Aug 2011   Two new studies suggest it might be easier to make a significant difference to people's risk of death than we think. Researchers in Taiwan found that just 15 minutes exercise a day appears to be enough to lengthen lifespan, even for people with cardiovascular disease, while researchers in Australia found that long hours spent watching TV can shorten lifespan. Both studies are published online this week, the first in The Lancet, the second in the British Journal of Sports Medicine. For the The Lancet study, Chi-Pang Wen of the Institute of Population Science at Taiwan's National Health Research Institutes, and colleagues, write that the benefits of physical activity, including links with longer lifespan, are well known, but we know little about the effects of exercising less than the widely recommended 150 minutes a week. To look into this further, they assessed the benefits of various amounts of exercise in over 400,000 people (approximately half men and half women) living in Taiwan who underwent standard medical screening between 1996 and 2008. As part of the screening the participants had filled in questionnaires about exercise, so that from their responses, the researchers were able to categorize them according to five levels of weekly exercise volume: inactive, low, medium, high, and very high. Then over an average follow up of 8 years, they noted any deaths among the cohort and calculated the risk of death of each of the four active groups compared to the inactive group, and the life expectancy of each group. They found that compared with the inactive group, the low volume exercise group had a 14% reduced risk of death from all causes (Hazard Ratio HR = 0·86, 95% Confidence Interval CI =0·81 to 0·91) and their life expectancy was 3 years longer. This group exercised on average 92 minutes a week (95% CI from 71 to 112 minutes a week) or 15 minutes a day. (SD 1.8). Bringing in the other active groups, they found that every extra 15 minutes of exercise per day above the 15 minutes per day of the low volume group, reduced risk of death from all causes by another 4% (95% CI from 2.5 to 7.0), death from all cancers by 1% (0.3-4.5). These results applied to all age groups, both men and women, and to participants with risks for cardivascular disease. Wen and colleagues also found that participants in the inactive group had a 17% higher risk of death compared with participants in the low-volume exercise group (HR 1.17, 95% CI 1.10 - 1.24). In the British Journal of Sports Medicine paper, researchers in Australia found that watching TV or videos for an average of six hours a day could shorten a person's lifespan by nearly five years. Lennert Veerman of the School of Population Health at the University of Queensland, and colleagues, used data from the Australian Diabetes, Obesity and Lifestyle Study, a national population-based observational survey that started in 1999-2000. This was a cross-sectional survey of Australian adults aged 25 and over that included information about TV viewing habits. They then cross-referenced the data against the Australian Bureau of Statistics national population and mortality figures for 2008. Using a "life table model" approach, they modelled the effect of changes in population average TV viewing time on life expectancy at birth: effectively estimating how long a person can expect to live depending on how many hours they spend watching the TV every day. Their results showed that compared to people who don't watch TV at all, those who spend an average of 6 hours a day watching TV can expect their lives to be 4.8 years shorter. They also found that every hour of TV viewing after the age of 25, took 22 minutes off a person's life expectancy. The researchers said these findings suggest the effect of TV viewing time on loss of life is comparable to that of other major chronic disease risk factors such as obesity and lack of exercise.

2nd Cross-Straits (Fuzhou) Medicine Expo scheduled to open in October

 17 Aug 2011  The second Cross-Straits (Fuzhou) Medicine Expo is scheduled from Oct 15 to Oct 17 at the Fuzhou Spring Exhibition Center. The expo will feature a joint conference on new medicines and a medical industry forum. On display will be medicines, medical instruments, medical cosmetics and information about medical institutions. Last year, more than 500 companies attended the cross-Straits expo, including 50 from Taiwan province.

國發基金投資案 成功的代名詞????

國發基金投資生醫成果多2011-08-17 工商時報  經建會副主委胡仲英昨（16）日表示，國發基金直接投資生技醫療近期展現重大發展機會，包括國光、神隆、太景、中裕新藥及智擎生技等五家企業均規畫上市櫃。副總統蕭萬長在致詞中提到，我國上市櫃生技公司家數持續增加，累計至去（2010）年底，共有46家上市櫃，市值高達2,107億元，去年民間生技產業投資金額，創下歷史新高，達新台幣301億元。政委朱敬一也說，台灣55家生技股，本益比30，是目前市場平均的2倍，顯示發展潛力看好。胡仲英表示，台灣生技醫療產業投資機會充沛，99年生技醫療產業產值2,286億元、企業總家數達1,355家、從業人員為5萬4,550人；其中580家為醫療器材產業、產值928億元，370家為製藥產業、產值725億元， 405家為新興生技產業、產值633億元。國發基金投資的生技醫療事業近期展現重大發展機會，其中規劃上市櫃者，包括國光、神隆、太景、中裕新藥及智擎生技；洽談技術授權者，包括健亞生技、太景醫藥及智擎生技。胡仲英說，像神隆公司，其癌症藥相關原料藥產品陸續成功上市，已為歐美國際藥廠原料藥的重要供應商；智擎生技今年5月才宣佈以2.2億美元，將其開發中治療癌症用藥授權給美國Merrimack Pharmaceuticals藥廠，此項授權的交易金額已打破台灣生技公司紀錄。國發基金已有5組生技團隊與國發基金洽詢投資申請，另有3組團隊向國發基金提出正式營運計畫申請投資。

國光生技: 徐小波/ 朱雲鵬獨董; 林秋雄監察人

國光生技：本公司100年股東臨時會董監事全面改選當選名單公告2011/8/15  鉅亨網 第三十四條　第6款1.發生變動日期:100/08/152.舊任者姓名及簡歷:董事:詹啟賢董事:耀華玻璃(股)公司管理委員會代表人：嚴重光董事:誠洲(股)公司代表人：廖繼誠董事:精茂投資股份有限公司代表人：林玉樹董事:陳曉堂獨立董事:朱雲鵬獨立董事:林秋雄監察人:南和興產股份有限公司代表人：陳田圃監察人:中國鋼鐵股份有限公司代表人：李慶超監察人:行政院國家發展基金管理會代表人：陳世賢3.新任者姓名及簡歷:董事:詹啟賢董事:廖繼誠董事:耀華玻璃(股)公司管理委員會代表人：嚴重光董事: 精茂投資股份有限公司代表人：林玉樹董事:南和興產股份有限公司代表人：陳田圃董事:陳曉堂獨立董事: 徐小波獨立董事:朱雲鵬獨立董事:林秋雄監察人:行政院國家發展基金管理會代表人：黃銘傑監察人:中國鋼鐵股份有限公司代表人：李慶超監察人:魏啟林4.異動情形（請輸入「辭職」、「解任」、「任期屆滿」或「新任」）:新任5.異動原因:全面改選6.新任董事選任時持股數:董事:詹啟賢 1,297,941股董事:廖繼誠 718,577股董事:耀華玻璃(股)公司管理委員會代表人：嚴重光 16,878,048股董事:精茂投資股份有限公司代表人：林玉樹 4,300,850股董事:南和興產股份有限公司代表人：陳田圃 1,539,809股董事:陳曉堂 208,903股獨立董事:徐小波 0股獨立董事:朱雲鵬 0股獨立董事:林秋雄 0股監察人:行政院國家發展基金管理會代表人：黃銘傑 31,747,438股監察人:中國鋼鐵股份有限公司代表人：李慶超 6,599,896股監察人:魏啟林 0股7.原任期（例xx/xx/xx至xx/xx/xx）:97/10/30~100/10/298.新任生效日期:100/08/15~103/08/149.同任期董事變動比率:係全面改選10.其他應敘明事項:無

 

Reference: 朱雲鵬/林秋雄/徐小波_國光生技董事之候選人